Latest Breaking News On - Anthonyg quinn - Page 1 : comparemela.com

Aeglea BioTherapeutics Announces European Medicines Agency Validation of Marketing Authorization Application for Pegzilarginase for the Treatment of Arginase 1 Deficiency

/PRNewswire/ Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to.

United statesAeglea biotherapeuticsAnthonyg quinnEuropean medicines agencyDrug administrationPrnewswire aeglea biotherapeutics incMarketing authorization applicationImmedica pharmaOrphan drugLabel extensionRare pediatric diseaseBreakthrough therapyFast trackOrphan drug designationEuropean medicines

Aeglea BioTherapeutics (AGLE) Announces EMA Validation of Marketing Authorization Application for Pegzilarginase for the Treatment of Arginase 1 Deficiency

Aeglea BioTherapeutics (AGLE) Announces EMA Validation of Marketing Authorization Application for Pegzilarginase for the Treatment of Arginase 1 Deficiency
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Anthonyg quinnEuropean medicines agencyAeglea biotherapeutics incMarketing authorization applicationImmedica pharmaOrphan drug

Analysts Expect Aeglea BioTherapeutics, Inc (NASDAQ:AGLE) Will Post Quarterly Sales of $1 42 Million

Wall Street analysts expect Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE – Get Rating) to announce $1.42 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Aeglea BioTherapeutics’ earnings, with estimates ranging from $1.34 million to $1.50 million. Aeglea BioTherapeutics posted sales of $13.70 million in the same […]

Aeglea biotherapeuticAeglea biotherapeuticsPiper sandlerAnthonyg quinnZacks investment researchPinnacle wealth planning services incNeedham companyNisa investment advisorsAeglea biotherapeutics incCitigroup incRoyal bankWall streetGet ratingZacks investmentInvestment researchWealth planning services

Aeglea BioTherapeutics (AGLE) Receives Refusal to File Letter from FDA for Pegzilarginase for the Treatment of Arginase 1 Deficiency

Aeglea BioTherapeutics (AGLE) Receives Refusal to File Letter from FDA for Pegzilarginase for the Treatment of Arginase 1 Deficiency
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Anthonyg quinnEuropean medicines agencyDrug administrationAeglea biotherapeutics incBiologics license applicationChemistry manufacturingMiddle eastMarketing authorization applicationRare pediatric diseaseBreakthrough therapyFast trackOrphan drug

Piper Sandler Lowers Aeglea BioTherapeutics (NASDAQ:AGLE) to Neutral

Aeglea BioTherapeutics (NASDAQ:AGLE – Get Rating) was downgraded by analysts at Piper Sandler from an “overweight” rating to a “neutral” rating in a report released on Thursday, The Fly reports. They currently have a $1.00 target price on the biotechnology company’s stock, down from their prior target price of $4.00. Piper Sandler’s price objective points […]

Aeglea biotherapeuticsJonathan alspaughPiper sandlerAnthonyg quinnSecurities exchange commissionBain capital life sciences investorsZacks investment researchBlackrock incAeglea biotherapeutics company profile get ratingSuvretta capital managementNantahala capital managementAeglea biotherapeutics incGet ratingInvestment researchExchange commissionCapital management